Laurie H. Glimcher, MD
President and CEO, Dana-Farber Cancer Institute
Richard and Susan Smith Professor of Medicine, Harvard Medical School
Director, Dana-Farber/Harvard Cancer Center
Laurie H. Glimcher, M.D., is the president and CEO of the Dana-Farber Cancer Institute, director of the Dana-Farber/Harvard Cancer Center and the Richard and Susan Smith Professor of Medicine at Harvard Medical School. Previously, she was the Stephen and Suzanne Weiss Dean and Professor of Medicine of Weill Cornell Medicine and Provost for Medical Affairs of Cornell University.
She is a member of the National Academy of Sciences, the National Academy of Medicine and the American Philosophical Society, fellow of the American Academy of Arts and Sciences and the former president of the American Association of Immunologists. She is a member of the Cancer Research Institute, Prix Galien, Parker Institute for Cancer Immunotherapy, Repare Therapeutics, Abpro Therapeutics, Kaleido BioSciences, Inc. Scientific Advisory Boards, the Lasker Award Jury, the American Association for Cancer Research, Association of American Cancer Institutes, and the American Society of Clinical Oncology and served on the Vice President’s Blue Ribbon panel. Dr. Glimcher previously served on the board of directors of Bristol-Myers Squibb Pharmaceutical Corporation and the Waters Corporation. She currently serves on the board of directors of GlaxoSmithKline Pharmaceutical Corporation and Analog Devices, Inc.
Dr. Glimcher’s research identified key transcriptional regulators of protective immunity and the origin of pathophysiologic immune responses underlying autoimmune, infectious and malignant diseases. Dr. Glimcher speaks nationally and internationally on cancer, immunology, and translational medicine and has contributed more than 350 scholarly articles and papers to the medical literature.
Aside from her research efforts, Dr. Glimcher has been a staunch proponent of improved access to care, health policy and medical education, while simultaneously serving as a pioneering mentor and role model for cancer research trainees and for all women in science. Notably, she was the first female to be appointed as dean of Weill Cornell Medicine in New York and is the first female president and chief executive officer of Dana-Farber Cancer Institute in Boston.